BR0316206A - Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos - Google Patents

Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos

Info

Publication number
BR0316206A
BR0316206A BR0316206-0A BR0316206A BR0316206A BR 0316206 A BR0316206 A BR 0316206A BR 0316206 A BR0316206 A BR 0316206A BR 0316206 A BR0316206 A BR 0316206A
Authority
BR
Brazil
Prior art keywords
edematous
neovascular
treatment
histone deacetylase
deacetylase inhibitors
Prior art date
Application number
BR0316206-0A
Other languages
English (en)
Inventor
Peter G Klimko
David P Bingaman
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0316206A publication Critical patent/BR0316206A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO INIBIDORES DE HISTONA DESACETILASE PARA O TRATAMENTO DE DISTúRBIOS E DE DOENçAS OCULARES NEOVASCULARES OU EDEMATOSOS". A presente invenção refere-se a composições oftálmicas contendo inibidores de HDAC e uso dos mesmos para o tratamento de doenças e distúrbios aculares neovasculares ou edematosos.
BR0316206-0A 2002-11-12 2003-10-30 Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos BR0316206A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42557402P 2002-11-12 2002-11-12
PCT/US2003/034617 WO2004043352A2 (en) 2002-11-12 2003-10-30 Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases

Publications (1)

Publication Number Publication Date
BR0316206A true BR0316206A (pt) 2005-09-27

Family

ID=32313018

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316206-0A BR0316206A (pt) 2002-11-12 2003-10-30 Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos

Country Status (12)

Country Link
US (3) US20060074100A1 (pt)
EP (1) EP1560583A4 (pt)
JP (1) JP2006512318A (pt)
KR (1) KR20050086526A (pt)
CN (1) CN1711087A (pt)
AU (1) AU2003287349B2 (pt)
BR (1) BR0316206A (pt)
CA (1) CA2504460A1 (pt)
MX (1) MXPA05004485A (pt)
RU (1) RU2352337C2 (pt)
WO (1) WO2004043352A2 (pt)
ZA (1) ZA200503237B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043352A2 (en) * 2002-11-12 2004-05-27 Alcon, Inc. Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
AU2004228011A1 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
JP4946861B2 (ja) * 2004-08-09 2012-06-06 アステラス製薬株式会社 ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物
US7772245B2 (en) 2005-02-14 2010-08-10 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
EP1877098B1 (en) * 2005-05-05 2013-04-24 Chroma Therapeutics Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
JP2009501236A (ja) 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2007014327A2 (en) * 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
ATE554084T1 (de) * 2006-02-07 2012-05-15 Astellas Pharma Inc N-hydroxyacrylamidverbindungen
WO2007113644A2 (en) * 2006-04-05 2007-10-11 Orchid Research Laboratories Limited New hdac inhibitors
CN101553475B (zh) * 2006-10-30 2013-04-24 色品疗法有限公司 作为组蛋白脱乙酰基酶抑制剂的异羟肟酸
MX2009006129A (es) * 2006-12-15 2009-06-18 Astellas Pharma Inc Compuestos de n-hidroxiacrilamida.
CN101239929B (zh) * 2007-02-09 2013-04-17 中国科学院上海药物研究所 曲古抑菌素a衍生物及其制备方法和用途
JP2008266321A (ja) * 2007-03-28 2008-11-06 Santen Pharmaceut Co Ltd フェニレンジアミン誘導体を有効成分とする眼圧下降剤
KR102341446B1 (ko) * 2016-09-29 2021-12-21 네이처와이즈 바이오테크 & 메디칼스 코포레이션 안구 질병을 치료하는 방법
US11253480B2 (en) * 2017-10-30 2022-02-22 University of Pittsburgh—of the Commonwealth System of Higher Education Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor
KR102236356B1 (ko) 2017-11-24 2021-04-05 주식회사 종근당 루푸스의 예방 또는 치료를 위한 조성물
KR20190099952A (ko) * 2018-02-20 2019-08-28 주식회사 종근당 포도막염의 예방 또는 치료를 위한 조성물
WO2019246509A1 (en) * 2018-06-22 2019-12-26 Mohan Rajiv R Methods and compositions for promoting wound healing with decreased scar formation after glaucoma filtration surgery
US20220008365A1 (en) * 2018-11-14 2022-01-13 Vanderbilt University Treating Intraocular Retinoblastoma with Inhibitors of Histone Modification
RU2769320C1 (ru) * 2020-12-28 2022-03-30 Федеральное государственное бюджетное учреждение науки Институт проблем химической физики Российской академии наук (ИПХФ РАН) Способ получения производных N-гидроксибутанамида

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
GB9804504D0 (en) * 1998-03-03 1998-04-29 Leo Pharm Prod Ltd Matrix metalloproteinase inhibitors
AUPP505798A0 (en) * 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
KR20010080142A (ko) * 1998-10-13 2001-08-22 후지야마 아키라 사이클릭 테트라펩티드 화합물 및 이의 용도
US6953783B1 (en) * 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
WO2000059865A1 (fr) * 1999-04-06 2000-10-12 Ono Pharmaceutical Co., Ltd. Derives d'acide 4-aminobutanoique et medicaments contenant ces derives en tant que principe actif
EA200601252A1 (ru) * 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
US6544957B2 (en) * 2000-01-04 2003-04-08 The Johns Hopkins University Methods and reagents for facilitating transcription
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
EP2269609A3 (en) * 2001-10-16 2012-07-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases and cancer of the brain with SAHA
US7154002B1 (en) * 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
RU2324483C2 (ru) * 2002-11-12 2008-05-20 Алькон, Инк. Ингибиторы гистондеацетилазы для лечения дегенеративных заболеваний глаз
WO2004043352A2 (en) * 2002-11-12 2004-05-27 Alcon, Inc. Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye

Also Published As

Publication number Publication date
RU2005118107A (ru) 2006-01-20
WO2004043352A2 (en) 2004-05-27
WO2004043352A3 (en) 2004-07-15
ZA200503237B (en) 2006-06-28
US20100048608A1 (en) 2010-02-25
CA2504460A1 (en) 2004-05-27
CN1711087A (zh) 2005-12-21
EP1560583A2 (en) 2005-08-10
AU2003287349A1 (en) 2004-06-03
US20040092558A1 (en) 2004-05-13
US20060074100A1 (en) 2006-04-06
AU2003287349B2 (en) 2009-04-23
EP1560583A4 (en) 2010-09-22
RU2352337C2 (ru) 2009-04-20
WO2004043352A8 (en) 2005-06-30
JP2006512318A (ja) 2006-04-13
MXPA05004485A (es) 2005-11-23
KR20050086526A (ko) 2005-08-30

Similar Documents

Publication Publication Date Title
BR0316206A (pt) Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
ATE414519T1 (de) Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
EA200501017A1 (ru) Астма и модуляторы аллергических воспалений
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
BR0312421A (pt) Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DK1465626T3 (da) Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
NO20055216D0 (no) Nye hydroksamater som terapeutiske midler
BR0308663A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
AU2003226014A1 (en) Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR0212014A (pt) Uso de derivados do ácido hidroxâmico inibidores da enzima histone deacetilase
ATE353319T1 (de) Acetylenderivate als inhibitoren von histondeacetylase
ATE465757T1 (de) Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0214672A (pt) Inibidores de fosfolipase citosólica a2
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]